This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Rating

10 Best Biotech Stocks for 2015

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks, by industry. The following biotech stocks are rated highest by our value-focused model. This list will be updated as upgrades and downgrades occur.

Equity Top: Biotechnology

Source: TheStreet Ratings

Best Investments for 2015

Biotechnology News

The newly approved Vertex pill, taken twice per day, is targeted at a genetic defect found in almost half of cystic fibrosis patients.
7/2/15 2:36PM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
7/2/15 12:54PM
The number of prescriptions written for MannKind's inhaled insulin drug Afrezza are barely making a dent in the diabetes market five months after partner Sanofi launched the product.
6/30/15 11:27AM
Under terms of the 10-year collaboration, Celgene is buying 9.1 million shares of Juno at $93 per share -- a 102% premium to Juno's closing price of $46.30.
6/29/15 5:10PM
Vertex Pharmaceuticals is widely expected to win U.S. approval later this week for a new drug which could one day treat almost half of cystic fibrosis patients.
6/29/15 11:06AM
New Sarepta CEO Ed Kaye filed for approval of eteplirsen with the FDA as promised, allowing him to check off a hugely important item on the company's to-do list.
6/29/15 7:02AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
6/26/15 6:01AM
Alcobra's MDX has now failed to demonstrate benefit for patients in two different clinical trials.
6/24/15 10:13AM
We've reached the stage of the biotech bull market where a sell-side analyst can value a company on sales of a cancer drug that doesn't even exist.
6/23/15 12:53PM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
6/19/15 6:00AM
I have some beefs with Leerink Partners biotech analyst Joe Schwartz and his research note in which he attempted to rebut my story about Receptos and the rampant takeout speculation.
6/18/15 8:52AM
Synergy Pharmaceuticals' experimental drug plecanatide significantly reduced chronic constipation compared to a placebo, achieving the primary goal of a late-stage study.
6/17/15 11:58AM
Lilly Ventures, the venture capital arm of the pharmaceutical giant with a seat on Receptos' board, just sold a good chunk of the company's stock.
6/17/15 11:05AM
I wanted to slam my forehead against the desk after the Avalanche CEO repeated for the 600th time, 'The key takeaway today is that it's a positive study.'
6/16/15 6:53AM
Agios shares are falling because investors thought the performance of its cancer drugs fell short, but only the method used to calculate response changed.
6/15/15 12:03PM

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%
Top Rated Stocks Top Rated Funds Top Rated ETFs